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Abstract: 
Histone deacetylase inhibitors (HDACIs) are a promising new class of anticancer drugs. 
However, their mechanism of action has not been fully elucidated. Most studies have 
investigated the effect of HDACIs on the regulation of gene transcription. HDAC inhibition 
also leads to genomic instability by a variety of mechanisms. This phenomenon, which has 
been largely overlooked, may contribute to the cytotoxic effects of these drugs. Indeed, 
HDACIs sensitize DNA to exogenous genotoxic damage and induce the generation of 
reactive oxygen species. Moreover, HDACIs target mitosis resulting in chromosome 
segregation defects. Here, we review the effects of HDACI treatment on DNA damage and 
repair, and chromosome segregation control. 
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1. Introduction: 
 
Although the presence of acetyl groups on histones and their role in transcription was first 
reported more than forty years ago [1; 2], the function of protein acetylation/deacetylation 
remained a relatively neglected field over the following thirty years. Since the identification 
of the first histone acetyltransferases (HATs) and histone deacetylases (HDACs) and their 
respective functions in regulation of transcription in the mid-90s [3-9], interest in previously 
overlooked protein post-translational modifications has been renewed [10-13]. There is now a 
growing body of evidence that protein acetylation is involved in a large number of cell 
signaling pathways, reminiscent of protein phosphorylation [14]. Protein acetylation is 
catalyzed by HATs, which transfer an acetyl group from acetyl-CoA to the ε-amino group of 
a lysine; the reverse reaction, involving the deacetylation of acetylated lysines, is mediated by 
HDACs. Acetylation and deacetylation by HATs and HDACs were first described for 
histones. However, these processes occur in bacteria [15; 16], which do not have histones. 
Indeed, a rapidly growing number of non-histone proteins have been found to be regulated by 
acetylation/deacetylation [17; 18]. 
There are four classes of HDAC in humans: class I HDACs (HDAC1, 2, 3 and 8) share 
sequence similarity with the yeast RPD3 deacetylase, are ubiquitously expressed and 
localized in the nucleus. Class II HDACs (HDAC4, 5, 6, 7, 9 and 10) are homologous to the 
yeast Hda1 deacetylase, are mainly cytoplasmic (or both nuclear and cytoplasmic) and 
restricted to certain tissues [19]. Class II HDACs are subdivided into two subclasses, class IIa 
(HDAC4, 5, 7 and 9) and class IIb (HDAC6 and 10). Class III HDACs are represented by 
sirtuins (SIRT1 to SIRT7), a family of seven HDACs sharing homology with yeast silent 
information regulator 2 (Sir2) [20]. In addition to their deacetylase activity, some sirtuins are 
able to transfer ADP-ribose from NAD+ to an acetylated protein target. Class IV has only one 
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member, HDAC11, which shares conserved residues with both class I and II HDACs [21]. 
Class I, II and IV HDACs activity requires Zn2+ and can be inhibited by a variety of different 
pharmacological HDAC inhibitors (HDACIs) [22], whereas class III enzymes are NAD+-
dependent deacetylases with only a limited number of inhibitors described [20; 23]. Class I, II 
and IV HDAC-specific inhibitors have antiproliferative activity and several are currently 
being tested in clinical trials, alone or in combination with other therapies, for their antitumor 
properties [24; 25]. There is now accumulating evidence of anticancer activity in myeloid 
malignancies and solid tumors for several HDACIs (reviewed in [26; 27]) and the first 
HDACI to obtain FDA approval for cancer therapy was suberoylanilide hydroxamic acid 
(SAHA, vorinostat), which was effective for the treatment of cutaneous manifestations of 
cutaneous T-cell lymphoma  in clinical trials [28]. Although HDACIs represent a new class of 
very promising anticancer drugs, their pleiotropic effects on a variety of cell functions make it 
difficult to identify the precise mechanism(s) underlying their antiproliferative properties. The 
most obvious target for HDACIs is gene expression; indeed, previous studies suggest that 
HDACI treatment (valproic acid, trybutirine, sodium butyrate [29] and SAHA [30]) leads to 
the reexpression of silenced tumor-suppressor genes, such as the p21(WAF1/CIP1)-encoding 
gene, in cancer cells. Some other specific targets for particular HDACIs have also been 
described. For example, treatment with valproic acid, but not trichostatin A (TSA), selectively 
induce proteasome dependent HDAC2 degradation [31]. However, potential downstream 
targets of HDACIs include various aspects of the cell cycle, DNA recombination and repair, 
extrinsic and intrinsic apoptosis pathways, angiogenesis, autophagy and senescence, among 
others; and it is not clear whether transcription mediates HDACI action in these processes 
[32]. Only a relatively small proportion of genes are up- or down-regulated following 
treatment with the HDACIs TSA [33-35], SAHA and MS-275[34]  and non-transcriptional 
targets have been proposed [36; 37].  
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A substantial number of studies have demonstrated a synergistic effect of conventional and 
HDACI-based therapies. In particular, HDACI treatments sensitize cycling cells to irradiation 
and DNA-targeting drugs, possibly resulting from HDACI-induced chromatin remodeling. 
Additionally, HDACIs seem to impair a variety of cellular processes that ensure genome 
stability, such as the control of DNA damage and repair, the regulation of reactive oxygen 
species (ROS) concentration and the progression into mitosis (relevant HDACIs and their 
known effects on genomic instability are listed on Table 1). Targeting genome integrity in 
rapidly cycling cells has always been a preferred strategy in cancer therapy; thus, in this 
review, we will focus on the different aspects of genome instability induced by 
pharmacological inhibition of Zn2+-dependent HDACs. 
 
2.  HDACIs and DNA damage and repair. 
 
There is no evidence suggesting that HDACIs have direct mutagenic or clastogenic properties. 
However, histone hyperacetylation induced by HDAC inhibition causes profound changes in 
chromatin structure. These changes may expose sections of DNA that are normally protected 
from damage in tightly packed chromatin. HDAC inhibition may also affect the expression of 
DNA repair genes and disrupt their finely-tuned expression timing, leading to improper 
cellular responses to DNA damage and accumulation of strand breaks and modified bases. 
Moreover, the activity of certain DNA repair proteins may be directly regulated by 
acetylation, resulting in a shift of the cellular acetylation/deacetylation balance towards 
hyperacetylation, and impaired DNA repair function. Thus, HDAC inhibition may indirectly 
exert clastogenic and mutagenic effects through DNA exposure and abnormal regulation of 
the DNA repair machinery.   
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2.1.  Sensitization to exogenous DNA damage by HDACI. 
 
Early observations indicated that the HDACI sodium butyrate enhances cell radiosensitivity in 
vitro [38-40]. Since these findings and the development of HDACIs as anticancer drugs, the 
number of studies reporting synergistic action between ionizing irradiation (IR) and HDACIs 
in cancer cell lines or animal pre-clinical models has grown exponentially. Various HDACIs, 
belonging to different chemical classes, appear to sensitize cultured cancer cells to IR 
(reviewed in [41]). In mouse xenograft models, the combination of HDACI treatment (MS-
275 [42], valproic acid [43], LBH589 [44], LAQ824 [45]and AN-9 [46]) with radiation 
therapy, results in a greater delay in tumor growth than that accounted for by a simple additive 
effect of the corresponding individual treatments. HDAC inhibition by LBH589 [44], TSA 
[47], depsipeptide [48] and SAHA [49] stabilizes and enhances IR-induced phosphorylated 
histone H2AX nuclear foci, classical markers of DSBs, suggesting that HDACIs inhibit DSB 
repair and/or render DNA more susceptible to IR-induced damage. HDACIs facilitate 
radiation-induced killing in tumor cells and at the same time appear to protect healthy tissues 
from cutaneous radiation syndrome. Although this hinders our understanding of the 
mechanisms involved, it will be a significant benefit for future therapies [50]. 
HDACIs such as HC-toxin, MS-275, SAHA and TSA also promote the induction of cell death 
by a variety of DNA-targeting drugs such as mitomycin C, cisplatin, bleomycin, topotecan, 
doxorubicin, etoposide, 5-fluorouracil and Ara-C [51; 52]. An HC-toxin induced increase in 
phosphorylated H2AX foci was observed for all drugs that directly, or indirectly, cause DSBs 
(mitomycin C, cisplatin, bleomycin, topotecan, doxorubicin and etoposide) [52]. This further 
supports the notion that HDAC inhibition stabilizes DSBs and/or increases DNA sensitivity to 
DSBs. In fission yeast, strains mutated for components of HDAC complexes are highly 
sensitive to genotoxic agents, with a massive accumulation of DSBs [53]. The same study 
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also demonstrated that these strains increase antisense transcripts, suggesting that DSBs could 
be triggered by the presence of RNA-DNA hybrids, structures known to induce genomic 
instability [54]. 
 
2.2.  HDACI and double strand break repair machinery. 
 
Spontaneous endogenous DNA double-strand breaks occur at the surprisingly high rate of 50 
DSBs per cell and per generation in normal cells [55]. Given that going through mitosis with a 
single unrepaired DSB is lethal in most cases, DSB repair mechanisms have to be remarkably 
efficient. Most DSBs are repaired by non homologous end joining (NHEJ) during the G1 
phase of the cell cycle, while the availability of a sister chromatid following DNA replication 
allows homologous recombination (HR) repair in S and G2 phases [56]. HDACIs alone do not 
induce DSBs but nevertheless induce a DNA-damage response [57]. Generating unstable 
DNA structures or making DNA more accesible to genotoxic agents may not be the only 
mechanism by which HDACIs sensitize cells to DNA damaging agents: histone 
acetylation/deacetylation also appears to be important for the DNA-damage response. In the 
yeast S. cerevisiae, HR triggers the transient acetylation of histones H3 and H4 N-terminal 
tails flanking a DSB. HDACs Rpd3, Sir2 and Hst1 are involved in the following deacetylation 
step, and RPD3 mutants show sensitivity to DSBs [58]. In addition, RPD3 deacetylates lysine 
16 on histone H4 in the vicinity of a DSB that can only be repaired by NHEJ. Consequently, 
RPD3 mutants also disrupt NHEJ, indicating that HDAC activity is also involved in the 
NHEJ-mediated DSB repair [59]. Time-course chromatin immunoprecipitation data suggest 
that HDACs are involved in restoring chromatin to its original conformation during the final 
steps of the DSB repair process [60]. Changes in the global chromatin configuration induced 
by HDACI treatment also promote DNA-damage signaling pathways, reflecting the 
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importance of the HAT/HDAC balance in determining an appropriate cellular response to 
DNA damage [57; 61]. In yeast, the DNA-damage response may be mediated by histone H3 
acetylation at lysine 16 (H3K16) by the HAT, Rtt109 [62; 63]. The sirtuins Hst3 and Hst4 
appear to be involved in the regulation of this H3K16-dependent DNA-damage response 
pathway [64]. In addition to their action on chromatin structure during DSB repair, HDACs 
can also affect the expression or activity of repair machineries. Treatments with the HDACIs 
TSA, SAHA, MS-275 and OSU-HDAC42 leads to acetylation of Ku70, a key NHEJ 
component, and sensitizes prostate cancer cells to DNA-damaging agents. This study showed 
that Ku70 acetylation does not affect the formation of a complex with its natural partner, 
Ku80; but, when the authors mimicked acetylation by replacing key lysines with glutamines, 
the ability of Ku70 to bind DNA extremities was suppressed [65]. HDACIs can also affect the 
expression of genes encoding HR components, as reported by two recent studies. Cell 
treatment with TSA induces down-regulation of a panel of genes involved in DNA repair, 
such as ATR (Ataxia telangiectasia-related, involved in DNA-damage signaling),  BLM 
(Bloom’s syndrome helicase, involved in collapsed replication fork repair), BRCA1 and -2 
(Breast Cancer 1 and -2, involved in HR) and NBS1 (Nijmegen breakage syndrome 1, 
involved in both DSB sensing and repair) [66]. In this study, TSA did not sensitize BRCA1-
null cells to irradiation, whereas a cell line complemented with a BRCA1 wild-type allele 
showed a TSA-dependent enhanced susceptibility to IR, suggesting that down-regulation of 
BRCA1 is a key event in HDACI-induced radiosensitization [66]. However, the picture is 
likely to be much more complex since this study did not detect a change in gene expression 
for the key strand transfer protein RAD51, whereas another group found that it was down-
regulated to one third of its normal levels following treatment with PCI-24781, another broad-
spectrum HDACI [67]. Consistent with HDACI-induced RAD51 depletion, treated cells 
exhibited HR repair defects and NHEJ mutant cells were hypersensitive to PCI-24781 [67]. 
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As recentely reported, deletion of a particular HDAC, HDAC3, in mouse embryonic 
fibroblasts affects S phase progression and causes DNA breaks, perhaps by disrupting DNA 
repair [68]. Consequentely, HDAC3 may represent an important target for HDACIs in terms 
of genomic instability.  
Thus, HDAC inhibition seems to promote the generation and stabilization of DNA DSBs by a 
pleiotropic mechanism. It sensitizes DNA to exogenous genotoxic damage, impairs the 
“DNA-damage histone code” function and down-regulates the activity of DNA repair 
machinery, either by acting on the expression of the corresponding genes or by directly 
inactivating the components by acetylation.  
 
2.3. HDACI-induced oxidative stress. 
 
Reactive oxygen species (ROS), such as superoxide anion, hydrogene peroxide or hydroxyl 
radicals, represent a major source of endogenous DNA damage. Normal cells control ROS 
concentrations through the actions of enzymatic and non-enzymatic ROS scavengers. 
However, cells with particularly high ROS concentrations, or with defective ROS scavengers, 
enter a state of genotoxic oxidative stress which often leads to apoptosis. The most widely 
studied mechanism of ROS-induced mutagenesis is base oxidation. Oxidized bases are 
normally removed by glycosylases. The resulting abasic site is then recognized by an AP-
endonuclease, which makes an incision on the DNA strand, generating a single-strand break 
(SSB) (reviewed in [69]). SSBs, which can also result from the direct oxidative damage of the 
nucleotide’s sugar component [70], are normally efficiently repaired to prevent their 
conversion into potentially lethal DSBs during DNA replication or transcription [71]. 
A number of studies have reported that HDAC inhibition by several HDACIs such as SAHA, 
MS-275, and NCH-51 leads to accumulation of ROS [72-76]. Furthermore, the resulting 
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oxidative stress seems to be involved in HDACI-induced cytotoxic effects, since co-treatment 
with ROS scavengers such as N-acetylcysteine decreases HDACI-induced cell death [72; 73; 
76]. SAHA treatment upregulates TBP2, an inhibitor of the ROS scavenger thioredoxin, 
possibly accounting for HDACI-induced accumulation of ROS [75; 77]. Notably, 8-
oxoguanine-DNA glycosylase 1 (OGG1) is regulated by acetylation. This enzyme is 
responsible for the removal of 8-oxoguanine, a common oxidative base lesion. OGG1 activity 
is stimulated by its acetylation and it associates with class I HDACs, which may be involved 
in its deacetylation [78]. Consequently, HDACI treatment may enhance oxidative DNA 
damage by both causing ROS accumulation and disrupting mechanisms involved in the repair 
of oxidative DNA lesions. 
Thus, by acting on chromatin conformation, disrupting the intracellular redox balance and 
deregulating repair mechanisms, HDACIs may induce extensive oxidative DNA damage. It is 
possible that the resulting accumulation of SSBs saturates repair mechanisms and that residual 
SSBs are converted to DSBs following DNA duplex unwinding during replication or 
transcription. The resulting chromosome fragmentation would then contribute to induction of 
apoptosis by HDACI. 
 
3.  HDACIs and control of chromosome segregation. 
 
Mitosis is a common target in anticancer therapy, as illustrated by the success of microtubule 
targeting drugs such as vinca alkaloids or taxanes. Inhibition of the main mitotic segregation 
control mechanism, the spindle assembly checkpoint (SAC), using RNA interference, leads to 
cell death in a few generations [79]. Thus, forcing rapidly cycling cells towards aneuploidy by 
damaging chromosome segregation control mechanisms may represent a novel therapeutic 
strategy. It now clear that HDAC inhibition also impairs the control of mitotic progression, 
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supporting the potential development of novel HDACI-based anticancer therapy targeting 
mitosis. 
 
3.1. HDACI effects on mitosis. 
 
Cells treated in culture with HDACI often display mitotic defects. One of the most striking 
effects of HDACI treatment is the disruption of pericentric heterochromatin associated with 
chromosomal segregation defects. Long-term incubation in TSA leads to loss of the 
heterochromatin-specific factor HP1 and to the appearance of lagging chromosomes [80]. 
HP1 proteins normally bind to a site encompassing histone H3 tri-methylated at lysine 9 by 
the histone methyl-transferase Suv39h [81; 82]. In fission yeast, HP1 and Suv39h orthologs 
are required for centromeric chromatid cohesion [83; 84]. It is thus possible that TSA-induced 
segregation defects result from abnormal acetylation of histone H3 on lysine 9, which would 
prevent Suv39h tri-methylation and inhibit HP1binding. Failure to bind HP1 proteins would 
in turn hamper heterochromatin formation and sister chromatid cohesion. However, a recent 
study demonstrated that, in contrast with fission yeast, the Suv39h-HP1 pathway is not 
required for chromatid cohesion in mammalian cells [85], suggesting that TSA-induced 
heterochromatin disruption and segregation defects may be unrelated.  
TSA-treated cells also exhibit chromosome condensation defects. Short-term treatment with 
high doses of TSA induces heterogeneity in chromosome condensation in all mitotic stages, 
associated with a delay in prophase progression and the occurrence of lagging chromosomes 
and chromatid bridges in anaphase [86]. In a Xenopus oocyte maturation system commonly 
used to mimic mitosis, TSA treatment impedes chromosome condensation without preventing 
meiosis progression [87]. Chromosome condensation is an essential step to eliminate DNA 
catenation at prophase and prevent chromosome missegregation at anaphase. The 
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condensation defects observed following HDAC inhibition may thus contribute to the 
segregation defects reported. 
HDAC inhibition may also disrupt mitosis by acting on mitotic kinases or their substrates. 
The class I histone deacetylase, HDAC3, targets chromosomes and associates with the mitotic 
kinase, Aurora B, during mitosis. Selective down-regulation of HDAC3 leads to a decrease of 
Aurora B-dependent phosphorylation of histone H3 on serine 10, and causes G2/M delay and 
segregation defects. The involvement of HDAC3 in providing a hypoacetylated histone H3 N-
terminal tail, the preferred substrate for Aurora B, has been suggested [88]. HDAC3 also 
seems to be involved in microtubule-kinetochore attachment and, may therefore have critical 
functions in different functional subcompartments during mitosis [89]. However the picture 
may be more complex since a recent study reported that, although HDAC3 knockout leads to 
embryonic lethality, no mitosis defects were observed in HDAC3-/- embryonic fibroblasts 
while these cells appear to be defective in DSB repair. [68]. Another mitotic kinase often 
overexpressed in cancer cells, Aurora A, may also represent a target for HDACIs. A recent 
study showed that the HDACIs LAQ824 and SK-7068 induced tumor-selective mitotic 
toxicity by depleting Aurora A. Treated cells had spindle defects and the mechanism by which 
Aurora A was down-regulated following treatment may involve stimulation of proteasome-
dependent degradation of Aurora A [90]. Mitotic spindle defects have also been reported 
using other HDACIs such as SBHA, SAHA, sodium butyrate and TSA[91].  
 
3.2. The spindle assembly checkpoint. 
 
Among their many effects, HDACIs appear to be potent pharmacological inhibitors of an 
essential segregation control mechanism: the mitotic spindle assembly checkpoint (SAC). The 
SAC maintains cells in mitosis with attached sister chromatids by preventing cyclin B and 
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securin proteasome-dependent degradation until all kinetochores have been captured by 
spindle microtubules and tension is established between sister kinetochores (reviewed in 
[92]). The SAC can be kept artificially activated by treating cells with the microtubule-
disrupting drug, nocodazole. Nocodazole-treated cells accumulate cyclin B and securin and 
can remain in a prometaphase-like state during several hours. Exit from mitosis in the 
presence of microtubule-disrupting drugs requires either loss of function of SAC or slow 
degradation of cyclin B in the presence of an active SAC (“mitotic slippage”) [93]. 
Nocodazole-arrested cells subsequently treated with HDACIs (SBHA or TSA) fail to 
accumulate cyclin B and associated cdk1 activity, suggesting that HDAC inhibition can 
induce exit from mitosis, despite nocodazole-induced SAC activation [94; 95]. Accordingly, 
in mitosis-arrested cells, TSA or SBHA treatment induces chromosome decondensation, 
nuclear membrane reformation, loss of phosphorylation on serine 10 of histone H3 and 
decreases the proportion of cells with 4 N DNA content [91; 95; 96]. Furthermore, key SAC 
proteins, such as Bub1, BubR1 and Mad2, fail to localize properly at the kinetochores 
following TSA treatment of nocodazole-arrested cells, suggesting a failure to maintain an 
active SAC when HDAC functions are disrupted [95-97]. In line with these findings, HDACIs 
(TSA, apicidin and sodium butyrate) induce premature sister chromatid separation [95], a 
phenotype consistently observed when the SAC is inhibited by RNA interference or genetic 
means [98-100]. Securin proteasome-dependent degradation is also observed in TSA treated 
mitotic cells and most likely accounts for premature sister chromatid separation [95]. A recent 
study reported that SBHA treatment results in failure to properly recruit the chromosomal 
passenger complex (CPC) at centromeres. Given that survivin and Aurora B, two essential 
CPC componants, control SAC protein localization [101-103], it was proposed that the 
HDACI-induced overriding of SAC results from CPC mistargeting [91]. Consistent with a 
role for HDACI in inhibiting the SAC, a synergistic effect of a combination of microtubule-
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targeting drugs with TSA has been reported [96]. Together, these findings demonstrate that 
HDAC inhibition leads to SAC dysfunction, providing a possible explanation for the previous 
observations that HDACIs treatments induce segregation defects and polyploidy [80; 86; 97; 
104].  
 
4. Conclusions and future directions. 
 
HDACIs appear to affect genome stability by targeting various cellular mechanisms of 
genome surveillance (outlined on Figure 1). This pleiotropic effect may explain why 
combinations of HDACIs and other genome-targeting agents, with different mechanisms of 
action,  often show synergetic effects. The variety of potential genomic HDACI targets and 
the other effects of HDAC inhibition on cellular functions should be considered when 
optimizing HDACI-based anticancer therapies. Accordingly, the order in which drugs are 
administered can be important for combined treatments involving HDACIs. For example, co-
treatment with SAHA or TSA and the topoisomerase II (Topo II) inhibitors VP-16 
(Etoposide) only has a synergistic effect if HDACIs are administrated before VP-16; indeed, 
the effect of  treatment with these drugs in the reverse order has no greater effect than with 
each drug alone, suggesting that HDACI-induced chromatin relaxation is required for 
increased efficacy of Topo II inhibitors [51]. Similarly, targeting mitosis and the SAC with 
HDACIs to cause gross aneuploidy in cancer cells is predicted to be effective only if the cells 
are first allowed to reach mitosis. However, many cells respond to HDACI treatment by up-
regulation of p21(WAF1/CIP1) and activation of the p38 MAPK checkpoint pathway, 
resulting in G1 and G2 arrest, respectively [29; 30; 105; 106]. Therefore, HDACI treatment 
aimed at overriding the SAC to cause a mitotic catastrophe, may require pretreatment with 
microtubule-targeting drugs, such as vinca alkaloids or taxanes, to accumulate cells in mitosis.  
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Targeting chromosome segregation to fight cancer may seem an attractive strategy but it must 
be remembered that forcing cells to chromosome missegregation is a double-edged sword 
since it appears to be both oncogenic and anti-oncogenic. As a matter of fact, mice 
heterozygous for the SAC components MAD1 and MAD2 are more susceptible to 
spontaneous tumors [99; 107], while down regulation of SAC component leads to 
proliferative cell death in an in vitro assay [79]. It was proposed that moderate chromosome 
missegregation could be tumorigenic while massive missegregation would lead to tumor 
suppression[108]. A recent and elegant study reports that mice heterozygous for the SAC 
component CENP-E had an increase incidence of spleen lymphomas and lung adenomas. 
However, the same animals had a decreased incidence of spontaneous liver cancers and of 
cancers chemically or genetically induced [109]. Thus, within the same organism, 
chromosome missegregation can act both as a tumor promoter and a tumor suppressor, 
depending on the cell type and the genetic and environmental contexts. This dual potential 
should be kept in mind when optimizing therapeutic protocols intended to target chromosome 
segregation for cancer therapy. 
Thus, the pleiotropic effect of nonspecific HDAC inhibition may hamper treatment targeting a 
given cellular function such as transcription, DNA repair or mitosis. As a consequence, the 
identification of the individual HDACs involved in these functions and the design of specific 
HDACIs that target single, or a small subset of, HDAC(s) remains a priority. 
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Figure legend: 
Figure 1: Schematic illustration of mechanisms of HDACI-induced genomic instability. 
Potential functional HDACI targets are boxed. See text for details on each mechanism. NHEJ, 
Non-Homologous-End-Joining; HR, Homologous Recombination. 
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Table 1. HDAC inhibitors and their action on genomic instability. 
 
Strutural class   HDACI  HDACs   Clinical trials** Effect on genomic  
       targeted*   (phase)  instability 
        
 
Hydroxamic acid-  TSA   Classes I and II     DDR, MD 
Derived compounds  SAHA   Classes I and II  FDA approval  DDR, OS, MD    
    LAQ824  Classes I and II  I   DDR, MD 
    LBH589  Classes I and II  I/II   DDR 
    PCI-24781         DDR 
    SBHA          MD 
 
Short-chain fatty acids Sodium butyrate Classes I and IIa     MD 
    Valproic acid  Classes I and IIa  I   DDR  
    AN-9       I/II   DDR 
    OSU-HDAC42        DDR    
 
Benzamides   MS-275  Class I (HDAC1,2 and 3) I/II   DDR, OS 
 
Cyclic peptides  Depsipeptide  (HDAC1,2, 4 and 6)  I/II   DDR 
    Apicidin         MD 
    HC-toxin         DDR 
 
Thiolate   NCH-51         OS 
 
 
*Data from {Kim, 2006 #456}{Rasheed, 2007 #453}; **Data from {Rasheed, 2008 #452; Rasheed, 2007 #453}. 
DDR : DNA damage and repair; OS: Oxidative stress; MD: Mitosis defects. 

